Shionogi & Co., Ltd.
Notice Regarding the Complete Acquisition of Torii Pharmaceutical Co., Ltd.
As of September 1, 2025, Shionogi & Co., Ltd. completed the acquisition of all shares of Torii Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary.
Key Figures
- Date of Wholly-Owned Subsidiary Acquisition: 2025-09-01
- Number of Shares Acquired: 10,977,091 shares (39.05%, as of June 25, 2025)
- Torii Pharmaceutical Net Sales (Fiscal Year Ending December 2024): 60,426 million JPY
AI要約
Overview of the M&A
Shionogi & Co., Ltd. commenced a tender offer for shares of Torii Pharmaceutical Co., Ltd. on May 8, 2025, acquiring 39.05% of the shares as of June 25, 2025, and made it an equity-method affiliate. Subsequently, on August 8, 2025, a share consolidation was executed, and on September 1, 2025, Torii Pharmaceutical completed a treasury stock acquisition by acquiring shares held by Japan Tobacco Inc., thereby making Torii Pharmaceutical a wholly-owned subsidiary.
Future Outlook and Impact
The impact on consolidated financial results due to the wholly-owned subsidiary acquisition is currently being examined, and will be promptly disclosed as necessary. Torii Pharmaceutical primarily engages in pharmaceutical manufacturing and sales, with sales and profits showing an increasing trend over the past three years.
